DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by DarioHealth Corp. (DRIO) on July 22, 2026. The filing discloses the entry into a Material Definitive Agreement regarding a registered direct offering of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 2,437,060 shares of Common Stock and pre-funded warrants to purchase 1,017,499 shares.
- Offering Prices: Common Stock at $6.80 per share; Pre-Funded Warrants at $6.7999 per share.
- Gross Proceeds: Approximately $23.5 million before deducting offering expenses.
- Director Participation: Board member Dennis Matheis agreed to purchase 14,430 shares at $6.93 per share.
- Placement Agent Fees: A.G.P./Alliance Global Partners engaged as sole placement agent with a cash fee of 6.0% of gross proceeds (1.0% for certain mutually agreed investors).
- Expense Reimbursement: Up to $60,000 for legal and other expenses incurred by the placement agent.
Material Changes and Restrictions
The Company entered into a 30-day "Restricted Period" following the closing of the Offering. During this time, the Company is prohibited from issuing or announcing the issuance of additional common stock or equivalents, with exceptions for the final prospectus supplement, Form S-8 filings for employee benefit plans, and sales under its existing At-The-Market facility.
Outlook, Risks, and Unusual Items
The Offering is expected to close on or about July 23, 2026, subject to customary closing conditions. Pre-Funded Warrants are exercisable immediately but are subject to beneficial ownership limitations (4.99% or 9.99% caps) to prevent holders from exceeding specific ownership thresholds without shareholder approval. The filing incorporates the full text of the Securities Purchase Agreement and Placement Agent Agreement by reference.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $23.5 million gross proceeds.
- Review the impact of the 30-day Restricted Period on future capital raising activities.
- Examine the specific terms of the Pre-Funded Warrants regarding exercise limitations and beneficial ownership caps.
- Confirm the net proceeds after deducting the 6.0% placement agent fee and the $60,000 expense reimbursement.
- Check subsequent filings for any updates on the use of proceeds or changes in the Company's liquidity position.